Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.

被引：4
|
作者：
Finn, Richard S.
Kudo, Masatoshi
Kang, Yoon-Koo
Yen, Chia-Jui
Galle, Peter R.
Llovet, Josep
Assenat, Eric
Brandi, Giovanni
Lim, Ho Yeong
Pracht, Marc
Rau, Kun Ming
Merle, Philippe
Motomura, Kenta
Ohno, Izumi
Daniele, Bruno
Shin, Dongbok
Gerken, Guido
Abada, Paolo
Hsu, Yanzhi
Zhu, Andrew X.
机构：
[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[5] Univ Med, Mainz, Germany
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] CHU Montpellier, Montpellier, France
[8] Univ Bologna, Dept Expt Diagnost & Specialty Med, Unit Oncol, Bologna, Italy
[9] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[10] Ctr Eugene Marquis, Rennes, France
[11] Kaohsiung Chang Gung Mem Hosp, Div Hematol Oncol, Kaohsiung, Taiwan
[12] Hop Croix Rousse, Dept Hepatol, Lyon, France
[13] Aso Iizuka Hosp, Fukuoka, Fukuoka, Japan
[14] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[15] G Rummo Hosp, Benevento, Italy
[16] Gachon Univ, Gil Med Ctr, Incheon, South Korea
[17] Univ Klinikum Essen AoR, Essen, Germany
[18] Eli Lilly & Co, Indianapolis, IN 46285 USA
[19] Eli Lilly & Co, New York, NY USA
[20] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.326
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
326
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study
    Zhu, Andrew X.
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Kudo, Masatoshi
    Poon, Ronnie Tung-Ping
    Pastorelli, Davide
    Blanc, Jean-Frederic
    Chung, Hyun Cheol
    Baron, Ari David
    Pfiffer, Tulio Eduardo Flesch
    Okusaka, Takuji
    Kubackova, Katerina
    Trojan, Jorg
    Sastre, Javier
    Chau, Ian
    Chang, Shao-Chun
    Abada, Paolo
    Yang, Ling
    Hsu, Yanzhi
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
    Chau, I.
    Park, J. O.
    Ryoo, B. Y.
    Yen, C. J.
    Poon, R.
    Pastorelli, D.
    Blanc, J. F.
    Kudo, M.
    Pfiffer, T. F.
    Hatano, E.
    Chung, H. C.
    Kubackova, K.
    Phelip, J. M.
    Brandi, G.
    Ohkawa, S.
    Li, C. P.
    Okusaka, T.
    Yang, L.
    Abada, P.
    Zhu, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S446 - S446
  • [3] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)
    Zhu, A. X.
    Finn, R. S.
    Galle, P. R.
    Llovet, J. M.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Cella, D.
    Girvan, A.
    Gable, J.
    Bowman, L.
    Hsu, Y.
    Abada, P. B.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 208 - 208
  • [4] Ramucirumab As Second-Line Treatment in Patients with Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following Sorafenib: Pooled Results from Two Global Phase 3 Studies (REACH-2 and REACH)
    Llovet, Josep M.
    Kudo, Masatoshi
    Finn, Richard
    Galle, Peter R.
    Blanc, Jean-Frederic
    Okusaka, Takuji
    Chau, Ian
    Abada, Paolo B.
    Hsu, Yanzhi
    Zhu, Andrew X.
    HEPATOLOGY, 2018, 68 : 166A - 166A
  • [5] Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
    Zhu, A. X.
    Galle, P. R.
    Llovet, J. M.
    Finn, R. S.
    Kang, Y-K.
    Yen, C. J.
    Assenat, E.
    Brandi, G.
    Motomura, K.
    Ohno, I.
    Daniele, B.
    Vogel, A.
    Yamashita, T.
    Hsu, C-H.
    Meyer, T.
    Widau, R.
    Schelman, W.
    Wang, C.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
    Kudo, Masatoshi
    Okusaka, Takuji
    Motomura, Kenta
    Ohno, Izumi
    Morimoto, Manabu
    Seo, Satoru
    Wada, Yoshiyuki
    Sato, Shinpei
    Yamashita, Tatsuya
    Furukawa, Masayuki
    Aramaki, Takeshi
    Nadano, Seijin
    Ohkawa, Kazuyoshi
    Fujii, Hirofumi
    Kudo, Toshihiro
    Furuse, Junji
    Takai, Hiroki
    Homma, Gosuke
    Yoshikawa, Reigetsu
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib
    Gerken, G.
    Zhu, A.
    Kang, Y-K
    Yen, C-J
    Finn, R.
    Galle, P.
    Llovet, J.
    Assenat, E.
    Brandi, G.
    Lim, H. Y.
    Pracht, M.
    Rau, K-M
    Merle, P.
    Motomura, K.
    Ohno, I
    Daniele, B.
    Shin, D. B.
    Abada, P. B.
    Hsu, Y.
    Kudo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 253 - 254
  • [8] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial
    Ohkawa, Shinichi
    Okusaka, Takuji
    Kudo, Masatoshi
    Hatano, Etsuro
    Fujii, Hirofumi
    Masumoto, Akihide
    Furuse, Junji
    Wada, Yoshiyuki
    Ishii, Hiroshi
    Obi, Shuntaro
    Arai, Kuniaki
    Kawazoe, Seiji
    Yokosuka, Osamu
    Ikeda, Masafumi
    Ukai, Katsuaki
    Morita, Sojiro
    Asou, Hiroya
    Abada, Paolo B.
    Yang, Ling
    Zhu, Andrew X.
    ANNALS OF ONCOLOGY, 2015, 26 : 94 - 94
  • [9] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
    Zhu, A.
    Finn, R.
    Galle, P.
    Llovet, J.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Abada, P.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).
    Shao, Guoliang
    Bai, Yuxian
    Chen, Xiaoming
    Gu, Shanzhi
    Gu, Kangsheng
    Yuan, Xianglin
    Widau, Ryan C.
    Zhang, Wanli
    Zhang, Qiang
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16081 - E16081
12345